The first two volunteers, one control (meningitis vaccine) and the other the vaccine treatment, were injected on April 23, 2020 for the Oxford University Phase I human vaccine clinical trials. [1]
The Oxford researchers started screening healthy volunteers (aged 18-55) in March 2020 for their upcoming ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region.
Seven days later on April 30, 2020 Oxford University announces partnership with AstraZeneca to help develop and distribute their COVID-19 vaccine.